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Lesson 
A 75-year-old man with an established diagnosis of liver cir-
rhosis secondary to non-alcoholic steato-hepatitis underwent 
primary endoscopic variceal ligation (EVL) for grade 3 oesopha-
geal varices after having been intolerant of propranolol as pri-
mary prophylaxis against variceal haemorrhage. He had a back-
ground history of type 2 diabetes mellitus, rheumatoid arthritis 
and atrial fibrillation. Eight days after EVL he suffered a profuse 
gastrointestinal bleed secondary to a ligation ulcer. The bleeding 
continued despite repeated endotherapy, terlipressin and the use 
of a Sengstaken Blakemore tube, thus necessitating insertion of 
a transjugular intrahepatic portosystemic shunt (TIPSS) that 
resulted in complete haemostasis. Until this admission the 
patient had been a keen artist (Fig 1).
One year later, the patient had enrolled in a postgraduate 
master of literature degree at university; however, he expressed 
frustration at loss of balance and intermittent confusion that was 
interfering with his studies. A clinical diagnosis of hepatic 
encephalopathy was confirmed by high levels of ammonia in 
serum on serial testing in the outpatient clinic. Hepatic encepha-
lopathy is a recognised complication of TIPSS, occurring in as 
many as 45% of patients and more commonly in older patients 
and those with renal impairment, hyponatraemia and hypoalbu-
minaemia.1 The patient started lactulose as treatment for hepatic 
encephalopathy, but this did not produce any significant 
improvement. Over time, the patient’s level of function deterio-
rated to the point where he could no longer study or paint and 
struggled even with handwriting (Fig 2). 
Subsequently, rifaximin was added to his prescription with 
dramatic improvement. He returned to his university studies 
and graduated successfully at the age of 75 years. Figure 3 shows 
examples of his handwriting and artwork after rifaximin was 
introduced. 
Discussion
Rifaximin has recently been identified as a safe, efficacious and 
cost-effective treatment for hepatic encephalopathy. It is a 
rifamycin-derived oral antibiotic that is more commonly associ-
ated with treatment of travellers’ diarrhoea. As rifaximin has 
almost no absorption from the gastrointestinal tract and does 
not induce cytochrome P450 enzymes, it is well tolerated, with 
few drug interactions or side effects.2 Importantly, rifaximin can 
be used safely in patients with liver disease to reduce production 
of ammonia by bacteria in the gut.
In patients with acute hepatic encephalopathy, rifaximin has 
shown comparable efficacy to lactulose.3 Bucci et al found that 
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Rifaximin may have a dramatic effect on 
hepatic encephalopathy
With a steadily increasing healthcare burden, all physicians 
must be aware of methods to manage the complications of 
chronic liver disease, including hepatic encephalopathy. 
Approved by the Food and Drug Administration in the USA 
and several European countries as a treatment for recurrent 
hepatic encephalopathy an increasing number of patients are 
now receiving rifaximin for this condition. This ‘lesson of the 
month’ highlights the dramatic effect that rifaximin may 
have on hepatic encephalopathy.
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Fig 1. Example of patient’s artwork prior to transjugular intrahepatic 
portosystemic shunt (TIPSS).
Fig 2. Example of patient’s handwriting during a period of hepatic 
encephalopathy.
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Rifaximin also seems to reduce the need for hospitalisation 
due to hepatic encephalopathy. An American study showed that 
although the monthly drug cost of rifaximin was higher than 
that for lactulose ($620 per month vs $50 per month), those 
receiving rifaximin required fewer hospitalisations over an 
observation period of one year and those who were admitted 
had a shorter average length of stay.4 Consequently, the total cost 
of therapy per patient per year was lower with rifaximin than 
with lactulose ($7,958 vs $13,285).
A further recent study in patients with recurrent hepatic 
encephalopathy in remission looked at the six-month incidence 
of breakthrough symptoms.5 These were noted in 22.1% of 
patients treated with rifaximin compared with 45.9% of those 
receiving placebo. More than 90% of patients in both arms 
received lactulose, which confirms that the addition of rifaximin 
may be very useful to control hepatic encephalopathy when 
monotherapy with lactulose is insufficient.
This lesson highlights pictorially the profound effect that this 
drug can have on the level of function of patients who experi-
ence hepatic encephalopathy. Clinicians should be aware of 
rifaximin as an additional or alternative agent to lactulose in the 
treatment of this condition.
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rifaximin was better tolerated than lactulose, with a limited 
number of side effects compared with the symptoms of diar-
rhoea, flatulence and dyspepsia experienced by about half of 
patients taking lactulose. In addition, patients’ mental state 
seemed to respond faster in those receiving rifaximin than in 
those taking lactulose.
Fig 3. Examples of patient artwork (a) and handwriting (b) after 
initiation of treatment with rifaximin.
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